Filing Details

Accession Number:
0001209191-18-021945
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-28 17:13:31
Reporting Period:
2018-03-26
Accepted Time:
2018-03-28 17:13:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1621227 Adaptimmune Therapeutics Plc ADAP () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559807 W. Peter Sonsini 2855 Sand Hill Road
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares With A Nominal Value Of 0.001 Gbp Per Share Acquisiton 2018-03-26 571,164 $1.90 73,978,672 No 4 P Indirect See Note 3
Ordinary Shares With A Nominal Value Of 0.001 Gbp Per Share Acquisiton 2018-03-27 6,000,000 $1.92 79,978,672 No 4 P Indirect See Note 3
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Note 3
No 4 P Indirect See Note 3
Footnotes
  1. The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 14, L.P. ("NEA 14"). NEA 14 holds these ordinary shares in the form of ADSs. Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. The ordinary shares reported in column 5 are represented by ADSs.
  2. The price reported in Column 4 of $1.9041 per ordinary share is a weighted average price derived from the weighted average price of $11.4247 per ADS, divided by six. These ADSs were purchased in multiple transactions at prices ranging from $11.17 to $12 per ADS, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The Reporting Person is a director of NEA 14 GP, LTD, which is the sole general partner of NEA Partners 14, L.P. ("NEA Partners 14"). NEA Partners 14 is the sole general partner of NEA 14, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 14 shares in which the Reporting Person has no pecuniary interest.
  4. The price reported in Column 4 of $1.9167 per ordinary share is a price derived from the price of $11.50 per ADS, divided by six.